Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy

Bevacizumab is thought to normalize tumor vasculature and restore the blood–brain barrier, decreasing enhancement and peritumoral edema. Conventional measurements of tumor response rely upon dimensions of enhancing tumor. After bevacizumab treatment, glioblastomas are more prone to progress as nonenhancing tumor. The RANO (Response Assessment in Neuro-Oncology) criteria for glioma response use fluid-attenuated inversion recovery (FLAIR)/T2 hyperintensity as a surrogate for nonenhancing tumor; however, nonenhancing tumor can be difficult to differentiate from other causes of FLAIR/T2 hyperintensity (eg, radiation-induced gliosis). Due to these difficulties, recent efforts have been directed toward identifying new biomarkers that either predict treatment response or accurately measure response of both enhancing and nonenhancing tumor shortly after treatment initiation. This will allow for earlier treatment decisions, saving patients from the adverse effects of ineffective therapies while allowing them to try alternative therapies sooner. An active area of research is the use of physiologic imaging, which can potentially detect treatment effects before changes in tumor size are evident.

[1]  Bradford A Moffat,et al.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. , 2006, Neoplasia.

[2]  Timothy D Johnson,et al.  Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Elke Hattingen,et al.  Prognostic value of choline and creatine in WHO grade II gliomas , 2008, Neuroradiology.

[4]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Hattingen,et al.  Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients , 2010, Journal of Neuro-Oncology.

[6]  G Johnson,et al.  Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. , 2000, AJNR. American journal of neuroradiology.

[7]  Kathleen M. Schmainda,et al.  Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri , 2010, Journal of Neuro-Oncology.

[8]  C. Marosi,et al.  [11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[9]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[10]  J. Smirniotopoulos,et al.  Glioblastoma multiforme: radiologic-pathologic correlation. , 1996, Radiographics : a review publication of the Radiological Society of North America, Inc.

[11]  T. Hirai,et al.  Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.

[12]  Ying Lu,et al.  Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume , 2004, Journal of magnetic resonance imaging : JMRI.

[13]  P. LaViolette,et al.  Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas , 2011, Journal of Neuro-Oncology.

[14]  Yue Cao,et al.  Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. , 2006, International journal of radiation oncology, biology, physics.

[15]  P. Box Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma , 2010 .

[16]  P. LaViolette,et al.  Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity , 2010, Journal of magnetic resonance imaging : JMRI.

[17]  William D Rooney,et al.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. , 2011, International journal of radiation oncology, biology, physics.

[18]  V. Levin,et al.  Effect of bevacizumab on radiation necrosis of the brain. , 2007, International journal of radiation oncology, biology, physics.

[19]  Kathleen M. Schmainda,et al.  Functional diffusion maps applied to FLAIR abnormal areas are valuable for the clinical monitoring of recurrent brain tumors , 2009 .

[20]  Steven C.R. Williams,et al.  Proc. Intl. Soc. Mag. Reson. Med. , 2012 .

[21]  P. Sundgren,et al.  Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. , 2009, AJR. American journal of roentgenology.

[22]  Thomas Czech,et al.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  K. Schmainda,et al.  Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. , 2008, Radiology.

[24]  J E Heiserman,et al.  Relative Cerebral Blood Volume Values to Differentiate High-Grade Glioma Recurrence from Posttreatment Radiation Effect: Direct Correlation between Image-Guided Tissue Histopathology and Localized Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging Measurements , 2009, American Journal of Neuroradiology.

[25]  A. McKinney,et al.  Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging , 2010 .

[26]  Wei Chen,et al.  Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Gereon R. Fink,et al.  Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  Heinrich Lanfermann,et al.  1H MRSI and progression-free survival in patients with WHO grades II and III gliomas , 2010, Neurological research.

[29]  R. Jain,et al.  Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[31]  P. Wen,et al.  Novel anti-angiogenic therapies for malignant gliomas , 2008, The Lancet Neurology.

[32]  Yue Cao,et al.  Clinical investigation survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT , 2006 .

[33]  M. Frosch,et al.  Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Nan,et al.  Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. , 2005, AJR. American journal of roentgenology.

[35]  E. Hattingen,et al.  Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[37]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[38]  Tracy T Batchelor,et al.  Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.

[39]  Wei Chen,et al.  18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[41]  Tom Mikkelsen,et al.  Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: Quality and analysis results of a phase I trial , 2004, Journal of magnetic resonance imaging : JMRI.

[42]  Olga Ciccarelli,et al.  Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. , 2009, Radiology.

[43]  M Takahashi,et al.  Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. , 2000, AJNR. American journal of neuroradiology.

[44]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[45]  C. Meyer,et al.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Raizer,et al.  Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. , 2010, Radiology.

[47]  Kathleen M. Schmainda,et al.  Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions , 2009 .

[48]  Marvin Bergsneider,et al.  Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.